Protein Kinase C Beta (PKC-Beta) Inhibitors Market - Forecast(2024 - 2030)

Report Code: HCR 0950 Report Format: PDF + Excel

Protein Kinase C Beta (PKC-Beta) Inhibitors Market Overview

Protein Kinase C Beta (PKC-Beta) Inhibitors Market size is estimated to reach $1.8 billion by 2027, growing at a CAGR of 6.8% during the forecast period 2022-2027. Protein Kinase C Beta (PKC-Beta) Inhibitors serve a role in keeping up normal nerve function. Its abnormal regulation can contribute to the pathogenesis of Diabetic Peripheral Neuropathy (DPN). The diacylglycerol kinases (DGK) are lipid kinases that convert diacylglycerol (DAG) into phosphatidic acid (PA) in a reaction that finishes DAG-based signals. DGK offer adverse regulation to traditional and novel protein kinase C (PKC) enzymes, binding regional DAG availability in a tissue- and subcellular-restricted manner. The important action of protein kinase C beta molecules in various cellular functions like gene expression, hormone secretion & cell growth and differentiation & the surging investigations involving ruboxistaurin mesylate is set to propel the growth of the Protein Kinase C Beta (PKC-Beta) Inhibitors Industry during the forecast period 2022-2027. This represents the Protein Kinase C Beta (PKC-Beta) Inhibitors Industry Outlook.

Protein Kinase C Beta (PKC-Beta) Inhibitors Market Report Coverage

The “Protein Kinase C Beta (PKC-Beta) Inhibitors Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Protein Kinase C Beta (PKC-Beta) Inhibitors Market.

by Therapy: Monotherapy and Combination Therapy.
by Drug Class: Phorbol Esters, Indolocarbazole, Macrocyclic Lactones, Nonsteroidal Anti-Oestrogen and Others.
by Route Of Administration: Intravenous, Oral and Others.
by Geography: North America (the US, Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and the Rest of the World (the Middle East and Africa).

Key Takeaways

  • Geographically, North America [Protein Kinase C Beta (PKC-Beta) Inhibitors Market share] accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the surging investigations pertaining to phospholipid-dependent serine/threonine kinases in the North American region.
  • Protein Kinase C Beta (PKC-Beta) Inhibitors Market growth is being driven by the high efficiency of treatment for diabetes, cardiac ailment and cancer. 
  • Protein Kinase C Beta (PKC-Beta) Inhibitors Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Protein Kinase C Beta (PKC-Beta) Inhibitors Market report.

Protein Kinase C Beta (PKC-Beta) Inhibitors Market: Market Share (%) by Region, 2021

Protein Kinase C Beta (PKC-Beta) Inhibitors Market

For More Details on This Report - Request for Sample

Protein Kinase C Beta (PKC-Beta) Inhibitors Market Segment Analysis - by Therapy

The Protein Kinase C Beta (PKC-Beta) Inhibitors Market based on therapy can be further segmented into Monotherapy and Combination Therapy. The Combination Therapy Segment held the largest Protein Kinase C Beta (PKC-Beta) Inhibitors Market share in 2021 and is estimated to grow with the fastest CAGR of 7.9% during the forecast period 2022-2027. This growth is owing to the extensive application of combination therapy. Combination therapy for hepatocellular carcinoma with diacylglycerol kinase alpha inhibition and anti-programmed cell death-1 ligand blockade has been investigated. Activation of diacylglycerol kinase alpha increases proliferation restrains cancer cell apoptosis and encourages T lymphocyte anergy. The surging investigations pertaining to combination therapy like the investigation of the impacts of combined treatment with rosuvastatin and LY333531, a selective protein kinase C (PKC) inhibitors, on angiogenesis under hyperglycemic conditions are further propelling the growth of the Combination Therapy segment. 

Protein Kinase C Beta (PKC-Beta) Inhibitors Market Segment Analysis - by Route of Administration

The Protein Kinase C Beta (PKC-Beta) Inhibitors Market based on the route of administration can be further segmented into Intravenous, Oral and others. The Oral Segment held the largest Protein Kinase C Beta (PKC-Beta) Inhibitors Market share in 2021 and is estimated to grow with the fastest CAGR of 7.6% during the forecast period 2022-2027. This growth is owing to the great safety offered by the oral route of administration. Protein kinase C (PKC) depicts a family of phospholipid-dependent serine/threonine kinases. Adenosine Triphosphate (ATP) has been delineated to trigger the phospholipase C/diacylglycerol/protein kinase C (PKC) pathway.

Protein Kinase C Beta (PKC-Beta) Inhibitors Market Segment Analysis - by Geography

The Protein Kinase C Beta (PKC-Beta) Inhibitors Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America [Protein Kinase C Beta (PKC-Beta) Inhibitors Market] held the largest Protein Kinase C Beta (PKC-Beta) Inhibitors Market share with 40% of the overall market in 2021. The growth of this region is owing to the existence of the U.S. which is a principal market in the North American region. The soaring and progressive R&D activities in the U.S. are further propelling the growth of the Protein Kinase C Beta (PKC-Beta) Inhibitors Industry, thereby contributing to the Protein Kinase C Beta (PKC-Beta) Inhibitors Industry Outlook in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the enormous population in the Asia-Pacific region. The surging count of novel entrants is further fuelling the progress of the Protein Kinase C Beta (PKC-Beta) Inhibitors Market in the Asia-Pacific region.

Protein Kinase C Beta (PKC-Beta) Inhibitors Market Drivers

Surging Applications of Protein Kinase C Beta (PKC-Beta) Inhibitors in Delineation:

Protein Kinase C (PKC) delineates a family of phospholipid-dependent serine/threonine kinases. Adenosine Triphosphate (ATP) has been displayed to stimulate the phospholipase C/diacylglycerol/protein kinase C (PKC) pathway. Experimental investigations showed the advantageous impacts of a PKC inhibitor on peripheral nerve dysfunction and nerve blood flow in diabetic rats. Integrating existing breast cancer therapies with new agents that intervene with principal signaling pathways is a favorable approach. Targeting protein kinase C (PKC)-beta can act as an appealing candidate in this regard for the following reasons: first, PKC-beta II (a splice variant of PKC-beta) has been suspected to be involved in tumorigenesis in human and rodent models. Second, PKC-beta, principally PKC-beta II, is the predominant mediator of vascular endothelial growth factor-induced endothelial cell proliferation, which is a well-recognized stimulator of tumor angiogenesis and growth in breast cancer. The PKC inhibitor, with activity against glycogen synthase kinase-3, enzastaurin (LY317615, Eli-Lilly, Indianapolis, Indiana), has shown action against glioma xenografts and has demonstrated likely clinical efficiency in a phase II trial of recurrent malignant gliomas with a 29% radiographic response rate. The surging applications of Protein Kinase C Beta (PKC-Beta) Inhibitors are therefore fuelling the growth of the Protein Kinase C Beta (PKC-Beta) Inhibitors Market during the forecast period 2022-2027.

Soaring Innovations in Protein Kinase C Beta (PKC-Beta) Inhibitors:

Protein Kinase C (PKC) is the portion of a class of intracellular signaling molecules activated in response to different particular hormonal, neuronal and growth factor stimuli. Adenosine Triphosphate (ATP) is displayed to stimulate the phospholipase C/diacylglycerol/protein kinase C (PKC) pathway. Ruboxistaurin mesylate, by inhibiting too much activation of some PKC isoforms, has the potential to decrease the burden of microvascular complexities for patients with diabetes. The data in an investigation pertaining to Ruboxistaurin mesylate and its role in treating diabetic nephropathy have demonstrated that ruboxistaurin considerably decreased albuminuria (an indicator of diabetic nephropathy) by 24%, as compared to a 9% decrease (nonsignificant) in patients taking placebo. These kinds of soaring innovations are contributing to the Protein Kinase C Beta (PKC-Beta) Inhibitors Industry Outlook during the forecast period 2022-2027.

Protein Kinase C Beta (PKC-Beta) Inhibitors Market Challenge

Limitations of Protein Kinase C Beta (PKC-Beta) Inhibitors:

Pooled data analysis from two equivalently planned, parallel, multinational, double-blind clinical trials of a selective endothelin A receptor antagonist, atrasentan, demonstrated a >35% decrease in albuminuria in participants of investigation enduring diabetic kidney disease (DKD) and no formerly noticed peripheral edema or heart failure. Numerous clinical trials of PKC inhibitors in cancers demonstrated no considerable clinical advantages. It means that there is a restraint to planning a cancer therapeutic strategy targeting Protein Kinase C (PKC) only. Protein kinase C-beta targeting demonstrated promising outcomes in preclinical and clinical investigations including an extensive assortment of cancers. However, investigations reporting the role of PKC in AIDS-NHL are ancient if not deficient. These issues are, thus, hampering the growth of the Protein Kinase C Beta (PKC-Beta) Inhibitors Market.

Protein Kinase C Beta (PKC-Beta) Inhibitors Industry Outlook

Progressive R&D activities are key strategies adopted by players in the Protein Kinase C Beta (PKC-Beta) Inhibitors Market. The top 10 companies in the Protein Kinase C Beta (PKC-Beta) Inhibitors Market are:

  1. Boehringer Ingelheim
  2. Eli Lilly and Company
  3. Novartis AG
  4. Takeda Pharmaceutical Company Limited
  5. AstraZeneca Plc.
  6. Keryx Biopharmaceuticals
  7. Pfizer Inc.
  8. Amgen Inc.
  9. Merck & Co.
  10. Zoetis Inc.

Relevant Reports:

Beta-lactam and Beta-lactamase Inhibitors Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 1436

Kinase Inhibitors Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0236

Depression Drugs Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0242

For more Lifesciences and Healthcare Market reports, please click here

1. Protein Kinase C Beta (PKC-Beta) Inhibitors Market Overview
    1.1 Definitions and Scope
2. Protein Kinase C Beta (PKC-Beta) Inhibitors Market - Executive Summary
3. Protein Kinase C Beta (PKC-Beta) Inhibitors Market – Market Landscape
    3.1 Company Benchmarking - Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Protein Kinase C Beta (PKC-Beta) Inhibitors Market – Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Protein Kinase C Beta (PKC-Beta) Inhibitors Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Protein Kinase C Beta (PKC-Beta) Inhibitors Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porter's five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Protein Kinase C Beta (PKC-Beta) Inhibitors Market – Strategic Analysis
    7.1 Value Chain Analysis 
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Protein Kinase C Beta (PKC-Beta) Inhibitors Market – by Therapy (Market Size – $Million/$Billion) 
    8.1 Monotherapy
    8.2 Combination Therapy
9. Protein Kinase C Beta (PKC-Beta) Inhibitors Market – by Drug Class (Market Size – $Million/$Billion) 
    9.1 Phorbol Esters
    9.2 Indolocarbazole
    9.3 Macrocyclic Lactones
    9.4 Nonsteroidal Anti-Oestrogen
    9.5 Others
10. Protein Kinase C Beta (PKC-Beta) Inhibitors Market – by Route Of Administration (Market Size – $Million/$Billion) 
    10.1 Intravenous
    10.2 Oral
    10.3 Others
11. Protein Kinase C Beta (PKC-Beta) Inhibitors Market - by Geography (Market Size - $Million/Billion)
    11.1 North America
        11.1.1 The US
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 Germany
        11.2.2 France
        11.2.3 The UK
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 The Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 Japan
        11.3.3 South Korea
        11.3.4 India
        11.3.5 Australia & New Zealand
        11.3.6 The Rest of Asia-Pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Chile
        11.4.4 Colombia
        11.4.5 The Rest of South America
    11.5 The Rest of The World
        11.5.1 The Middle East
        11.5.2 Africa
12. Protein Kinase C Beta (PKC-Beta) Inhibitors Market - Market Entropy
    12.1 New product launches
    12.2 M&A's, collaborations, JVs and partnerships
13. Protein Kinase C Beta (PKC-Beta) Inhibitors Market – Industry Competition Landscape (Premium)
    13.1 Market Share Analysis
        13.1.1 Market Share by Region – Key Companies
        13.1.2 Market Share by Countries – Key Companies
    13.2 Competition Matrix
    13.3 Best Practices for Companies
14. Protein Kinase C Beta (PKC-Beta) Inhibitors Market – Key Company List by Country Premium (Premium)
15. Protein Kinase C Beta (PKC-Beta) Inhibitors Market - Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
* "Financials would be provided to private companies on best-efforts basis."
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.